Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
CAMBRIDGE, Mass., May 01, 2018 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 1:30 PM ET in Boston, MA.
A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
